![]() |
市場調查報告書
商品編碼
2056561
藥物篩檢市場規模、佔有率、趨勢和預測:按產品/服務、檢體類型、最終用戶和地區分類,2026-2034 年Drug Screening Market Size, Share, Trends and Forecast by Product and Service, Sample Type, End User, and Region, 2026-2034 |
||||||
2025年全球藥物篩檢市場規模為73億美元,預計2034年將達到124億美元,2026年至2034年的複合年成長率為5.87%。目前,北美市場佔據主導地位,預計到2025年將佔據超過51%的市場。北美地區的成長主要得益於嚴格的職場法規、先進的檢測技術以及人們對藥物濫用日益增強的認知。
毒品和酒精消費量增加
毒品消費量的上升正在推動藥物篩檢產品需求的成長。例如,根據2023年歐洲毒品報告,歐盟約有8,340萬成年人(佔歐盟總人口的29%)報告至少使用過一次非法毒品。歐洲消費量最大的非法毒品是大麻,根據各國調查,估計2022年約有8%的歐洲成年人曾使用大麻。因此,許多人的吸毒行為影響了他們的生活,並增加了對藥物篩檢的需求,這反過來可能也是近期藥物篩檢市場價格上漲的原因之一。此外,隨著吸毒和酗酒人數的增加,對治療需求的增加預計將進一步提高醫院對藥物篩檢的需求。例如,根據英國政府網站GOV.UK發布的國家統計數據,截至2023年12月,約有290,635名成年人在2022年4月至2023年3月期間接受了藥物濫用問題的援助。與前一年約289,215人相比,略有成長。此外,同一份文件顯示,2022年至2023年間,約有137,749名成年人開始接受治療,超過了前兩年的數字(分別為130,490人和133,704人)。接受藥物濫用治療人數的顯著增加預計將提振藥物篩檢市場的需求。
政府法規
多項法律法規強制要求各行各業進行藥物和酒精檢測,這些法律的實施推動了對藥物篩檢產品和設備的需求。例如,2022年11月,美國聯邦汽車運輸安全管理局(FMCSA)發布了修訂後的藥物和酒精檢測要求。這些法規明確規定了哪些人應該接受檢測、檢測頻率以及在何種情況下需要進行檢測。此外,這些法規透過限制雇主和服務提供者使用和揭露敏感的藥物和酒精檢測資訊來保護員工隱私。除了法律規範外,各國政府也在努力幫助那些遭受嚴重成癮和藥物濫用困擾的人,這進一步擴大了藥物篩檢的市場佔有率。例如,印度政府的「無毒印度運動」(Nasha Mukt Bharat Abhiyaan)旨在透過各種活動(包括宣傳活動)提高公眾對藥物濫用的認知。同樣,加拿大政府也在投資藥物預防項目,以幫助那些與成癮作鬥爭的人克服藥物濫用問題。例如,位於亞伯達艾伯塔省卡加利的約翰霍華德協會致力於幫助 13 至 24 歲因吸毒而面臨輟學風險的年輕人。
檢測技術的進步
藥物篩檢技術的持續進步,包括快速檢測套組、實驗室檢測方法和即時檢測 (POC) 設備,透過提供更快、更準確、更經濟高效的篩檢解決方案,進一步推動了市場成長。此外,藥物篩檢技術的不斷改進提高了準確性和可靠性,降低了假陽性和假陰性的機率。這確保了檢測結果的可靠性,最大限度地減少了確認性檢測的需求,簡化了篩檢流程,並最終節省了成本。例如,2024 年 2 月,Mobile Health 在其紐約診所推出了一項新的快速藥物檢測服務,使雇主能夠輕鬆篩檢和僱用候選人。同樣,2023 年 10 月,ProciseDx Inc. 獲得了 FDA 的全新核准,用於針對Adalimumab(Humira 及其生物類似藥 Amgevita)和英夫利昔Infliximab(Remicade及其生物類似藥 Infractra 和 Renflexis)的治療藥物監測 (TDM) 檢測。這些名為Procise ADL和Procise IFX的檢測方法,用於定量檢測服用Adalimumab(ADL)和Infliximab(IFX)的發炎性腸道疾病(IBD)患者體內的藥物濃度。隨著越來越多的新藥檢測方法和設備獲得核准,預計未來幾年藥物篩檢市場將實現收入成長。
The global drug screening market size was valued at USD 7.3 Billion in 2025. Looking forward, it is estimated that the market to reach USD 12.4 Billion by 2034, exhibiting a CAGR of 5.87% from 2026-2034. North America currently dominates the market, holding a market share of over 51% in 2025. The growth of the North American region is driven by stringent workplace regulations, advanced testing technologies, and increased substance abuse awareness.
Major Market Drivers: Increasing demand for drug screening as it is accurate and provides spontaneous results is primarily driving the growth of the market. Furthermore, the rising cases of substance abuse around the world are also propelling the global market.
Key Market Trends: The integration of advanced technologies such as automation, artificial intelligence (AI), and molecular diagnostics with drug screening tests to streamline workflows, reduce human errors, and enhance testing is acting as one of the significant key trends, bolstering the market growth.
Competitive Landscape: Some of the leading drug screening market companies include Abbott Laboratories, Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Dragerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Lifeloc Technologies Inc., Omega Laboratories Inc., OraSure Technologies Inc., Psychemedics Corporation, Quest Diagnostics Incorporated, Siemens AG, and Thermo Fisher Scientific Inc., among others.
Geographical Trends: According to the report, North America is the largest market for drug screening. The growth of the region can be attributed to the escalating cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs.
Challenges and Opportunities: The drug screening market faces hurdles related to the development of accurate and reliable tests, overcoming false positives and negatives, and addressing privacy and ethical concerns regarding sample collection and testing procedures. Opportunities lie in the integration of advanced technologies such as AI and machine learning for data analysis and the development of portable and point-of-care testing devices for convenient and rapid screening applications.
Rise in Drug and Alcohol Consumption
The increasing consumption of drugs is resulting in an increased demand for drug-screening products. For instance, according to the 2023 European Drug Report, approximately 83.4 million adults (29%) in the European Union have reportedly used illicit drugs at least once. Cannabis is the predominant illicit drug consumed in Europe, with an estimated 8% of European adults using it in 2022, based on national surveys. Thus, a high number of the population consumes drugs, which impacts the lives of individuals and is likely to increase demand for drug screening, thereby bolstering the drug screening market's recent price. Additionally, the rising utilization of drugs and alcohol, along with the need for treatment, is anticipated to drive up the demand for drug screening in hospitals. For instance, as per National statistics published by GOV. UK, in December 2023, between April 2022 and March 2023, around 290,635 adults received support for substance use issues. This is a small rise compared to the previous year, around 289,215. Moreover, the same source stated that the number of adults entering treatment from 2022 to 2023 was approx. 137,749, which is higher than the previous two years' figures of 130,490 and 133,704. Such a significant rise in the number of people undergoing substance use is anticipated to propel the drug screening market demand.
Government Regulations
Several laws and regulations mandate drug and alcohol testing in various sectors, and the implementation of such laws is augmenting the demand for drug-screening products and devices. For instance, in November 2022, the Federal Motor Carrier Safety Administration (FMCSA) released updates outlining the drug and alcohol testing requirements. These regulations specify the individuals subject to testing, the frequency of testing, and the circumstances triggering testing. Additionally, the regulations safeguard employee privacy by limiting the use and disclosure of sensitive drug and alcohol testing information by employers and service agents. Besides the regulatory framework, government authorities of various nations are also taking initiatives to help severe addicts and individuals suffering from drug abuse, which is further propelling the drug screening market share. For instance, Nasha Mukt Bharat Abhiyaan is a program by the Indian Government that intends to reach out to the masses and spread awareness about substance abuse through various activities like awareness generation programs. Similarly, the government authorities of Canada are also investing in anti-drug strategy projects to help people with addiction come out of substance abuse. For example, the Calgary John Howard Society in Alberta, Canada, focuses on assisting youths aged 13 to 24 who face the risk of school dropout due to drug addiction.
Advancements in Testing Technologies
Ongoing advancements in drug screening technologies, such as rapid testing kits, laboratory-based assays, and point-of-care devices, are further driving the market growth by offering faster, more accurate, and cost-effective screening solutions. Moreover, the continuous improvement of drug screening technologies is resulting in enhanced accuracy and reliability and reduced likelihood of false positives or false negatives, ensuring confidence in test results and minimizing the need for confirmatory testing, thereby streamlining the screening process and reducing costs. For instance, in February 2024, Mobile Health introduced a new rapid drug testing service in New York clinics for employers to screen and hire candidates easily. Similarly, in October 2023, ProciseDx Inc. received de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis). These assays, called Procise ADL and Procise IFX, are used to quantify adalimumab (ADL) and infliximab (IFX) in patients suffering from inflammatory bowel diseases (IBD) who are taking these drugs. Increasing approval of new drug tests and instruments is anticipated to propel the drug screening market revenue in the coming years.
This report provides an analysis of the key trends in each segment of the global drug screening market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on product and service, sample type, and end user.
Rapid testing devices represented the largest segment
The drug screening market report has provided a detailed breakup and analysis of the drug screening market based on the product and service. This includes equipment (immunoassay analyzers, chromatography instruments, and breath analyzers); rapid testing devices (urine testing devices and oral fluid testing devices); consumables (assay kits, sample collection cups, calibrators and controls, and others); and laboratory services. According to the report, rapid testing devices (urine testing devices and oral fluid testing devices) represented the largest segment.
Rapid drug screening test devices are portable, easy-to-use tools designed for quick detection of drugs in various sample types, such as urine, saliva, or blood. These devices offer several benefits, including rapid results within minutes, enabling on-the-spot decision-making in scenarios like workplace testing or roadside screening. Their simplicity allows for minimal training requirements, making them accessible to a wide range of users. Moreover, rapid tests are cost-effective, reducing the need for laboratory analysis and turnaround time. For instance, Drager, a German company based in Lubeck that makes breathing and protection equipment, gas detection and analysis systems, and non-invasive patient monitoring technologies, introduced a rapid test named DrugTest 5000. In this test, saliva samples can be analyzed immediately for an accurate result on the spot. Furthermore, rapid screening devices play a crucial role in emergencies, aiding in the quick identification of drug intoxication or overdose for prompt medical intervention.
Urine samples accounted for the largest market share
As per the drug screening market overview, urine sample drug testing offers several benefits, making it a preferred method over other sample types in many scenarios. Firstly, urine testing is non-invasive and relatively easy to collect, minimizing discomfort and ensuring employee cooperation. Secondly, urine samples can detect a wide range of drugs and their metabolites, providing comprehensive screening capabilities. Thirdly, urine testing is cost-effective and suitable for high-volume testing, making it practical for workplace screening programs. Furthermore, urine testing is capable of detecting recent drug use, making it suitable for detecting impairment in safety-sensitive industries. Lastly, this testing is less susceptible to adulteration or tampering compared to other sample types, ensuring the integrity and reliability of test results.
Workplaces accounted for the largest market share
Drug screening tests in workplaces are conducted to detect the presence of drugs or alcohol in employees. These tests are typically performed as part of pre-employment screening, random testing, post-accident testing, or reasonable suspicion testing. The aim is to ensure a safe and productive work environment, minimize the risk of accidents and injuries, and deter substance abuse among employees.
North America (the United States and Canada) was the largest market for drug screening
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for drug screening.
Some of the factors driving the North America drug screening market included the growing cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs. Moreover, drug screening market statistics indicate that the growing substance abuse rates in the region are bolstering the need for drug screening. For instance, in February 2023, according to an article published by the Pennsylvania State University, around 63% of adults aged 18 years and above were reported to alcohol consumption in the United States in 2022. Among these, males (66%) had higher alcohol consumption as compared to females (61%). Thus, the large number of alcohol consumers raises the need for drug-testing products and services and is augmenting the market growth in North America. Moreover, the government authorities of North America are mandating drug screening tests in various sectors, which is further catalyzing the market growth. For instance, in May 2023, the United States Department of Transportation regulated the drug testing program by including oral fluid testing to improve safety and reduce the chances of cheating involved with urine drug tests.